	US 11,697,816 B2
	Artificial nucleic acid molecules
Stefanie Grund, Stuttgart (DE); and Thomas Schlake, Gundelfingen (DE)
Assigned to CureVac SE, Tübingen (DE)
Filed by CureVac SE, Tübingen (DE)
Filed on Jun. 28, 2016, as Appl. No. 15/195,524.
Application 15/195,524 is a continuation of application No. PCT/EP2014/003481, filed on Dec. 30, 2014.
Claims priority of application No. PCT/EP2013/003948 (WO), filed on Dec. 30, 2013.
Prior Publication US 2016/0304883 A1, Oct. 20, 2016
Int. Cl. A01N 63/00 (2020.01); C07H 21/04 (2006.01); C12N 5/00 (2006.01); C12N 15/68 (2006.01); C12N 15/85 (2006.01); C12N 15/67 (2006.01); A61K 39/00 (2006.01); A61K 48/00 (2006.01)

CPC C12N 15/68 (2013.01) [C12N 15/67 (2013.01); C12N 15/85 (2013.01); A61K 39/00 (2013.01); A61K 48/00 (2013.01); C12N 2800/107 (2013.01); C12N 2800/22 (2013.01); C12N 2830/00 (2013.01); C12N 2830/50 (2013.01); C12N 2840/203 (2013.01)]

22 Claims

1. An artificial nucleic acid molecule comprising

a) at least one open reading frame (ORF) encoding a pathogen antigen, tumor antigen or a human therapeutic protein,

b) at least one Sac Domain-Containing Inositol Phosphatase 3 (FIG4) 3′-untranslated region element (3′-UTR element) comprising a nucleic acid sequence from a human FIG4 gene 3′-UTR, and

c) a poly(A) sequence having a length of 40 to 200 adenine nucleotides,

wherein said ORF is heterologous to said 3′-UTR element and wherein said 3′-UTR element is positioned between said ORF and said poly(A) sequence.